盟科药业-U
(688373)
| 流通市值：17.77亿 | | | 总市值：33.55亿 |
| 流通股本：3.47亿 | | | 总股本：6.55亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 33,016,131.56 | 90,776,385.24 | 68,272,315.43 | 42,110,171.77 |
| 营业收入 | 33,016,131.56 | 90,776,385.24 | 68,272,315.43 | 42,110,171.77 |
| 二、营业总成本 | 140,526,292.61 | 538,482,151.17 | 335,652,567.97 | 184,852,221.21 |
| 营业成本 | 5,809,493.11 | 16,695,863.64 | 12,503,164.6 | 7,865,572.56 |
| 税金及附加 | 68,495.49 | 296,271.78 | 162,454.61 | 119,441.11 |
| 销售费用 | 30,288,099.31 | 107,406,779.7 | 69,158,041.5 | 44,729,290.84 |
| 管理费用 | 16,836,390.43 | 61,165,618.06 | 43,340,308.88 | 30,085,060.67 |
| 研发费用 | 84,646,910.43 | 344,861,801.85 | 202,949,875.3 | 96,098,409.76 |
| 财务费用 | 2,876,903.84 | 8,055,816.14 | 7,538,723.08 | 5,954,446.27 |
| 其中:利息费用 | 1,225,579.36 | 10,135,035.97 | 7,390,136.51 | 5,332,220.54 |
| 其中:利息收入 | 1,223,448.42 | 2,185,334.04 | 1,486,777.58 | 894,815.03 |
| 加:公允价值变动收益 | 5,293,182.67 | 33,343,844.05 | 27,132,206.65 | 21,489,403.45 |
| 资产处置收益 | - | 1,459.62 | 1,459.62 | 1,459.62 |
| 信用减值损失(新) | -98,618.82 | -328,022.54 | -174,794.53 | 114,058.34 |
| 其他收益 | 184,777.34 | 3,784,662.76 | 198,462.76 | 198,462.76 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -102,130,819.86 | -410,903,822.04 | -240,222,918.04 | -120,938,665.27 |
| 减:营业外支出 | 5,803.81 | 4,249,336.21 | 4,230,089.2 | 4,178,408.23 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -102,136,623.67 | -415,153,158.25 | -244,453,007.24 | -125,117,073.5 |
| 减:所得税费用 | - | 5,971,294.4 | 5,611.86 | 5,543.3 |
| 六、净利润 | -102,136,623.67 | -421,124,452.65 | -244,458,619.1 | -125,122,616.8 |
| 持续经营净利润 | -102,136,623.67 | -421,124,452.65 | -244,458,619.1 | -125,122,616.8 |
| 归属于母公司股东的净利润 | -102,136,623.67 | -421,124,452.65 | -244,458,619.1 | -125,122,616.8 |
| (一)基本每股收益 | -0.16 | -0.64 | -0.37 | -0.19 |
| (二)稀释每股收益 | -0.16 | -0.64 | -0.37 | -0.19 |
| 八、其他综合收益 | 673,642.43 | 3,714,041.65 | 10,842,714.39 | 12,150,057.27 |
| 归属于母公司股东的其他综合收益 | 673,642.43 | 3,714,041.65 | 10,842,714.39 | 12,150,057.27 |
| 九、综合收益总额 | -101,462,981.24 | -417,410,411 | -233,615,904.71 | -112,972,559.53 |
| 归属于母公司股东的综合收益总额 | -101,462,981.24 | -417,410,411 | -233,615,904.71 | -112,972,559.53 |
| 公告日期 | 2024-04-26 | 2024-03-28 | 2023-10-27 | 2023-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |